CMS’s aim to cut documentation will be a payment cut

When CMS proposed several changes to the Physician Fee Schedule and Quality Payment Program in July, it was under the guise that the agency was knocking off burdensome documentation requirements for physicians. Presumably, the less time doctors spent on paperwork, the more they could be with patients.

However, the agency’s own proposal states documentation time won’t actually be reduced by much—but the changes will likely come with a payment rate cut.

“CMS says it will save something like 500 years in documentation,” Drew Voytal, MPA, associate director of government affairs for the Medical Group Management Association, said during a recent presentation in Boston at the association’s annual convention.

However, digging a little further into the proposal, “CMS themselves say, really, we don’t think this will cut documentation,” Voytal said.

One key part of the proposal that will result in a payment cut is CMS’s idea to overhaul evaluation/management (E/M) coding and payment policies by creating one payment rate for four different levels of office and outpatient E/M visits. Doing so effectively reduces the payment rate for codes 4 and 5. Under the notion of cutting documentation, the proposal would actually reduce payments with few documentation adjustments.

“It’s important to know they think they buried the book about it,” Voytal said.

The association also called the proposals “misguided.”

The changes in the proposed rule are far-reaching, but the E/M coding changes have “gotten the most attention” from providers as a result of the possible rate cut, according to MGMA.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.